Effects of pioglitazone on insulin sensitivity and serum lipids in obese cats.

ABSTRACT:

Background

Pioglitazone is a thiazolidinedione (TZD) insulin sensitizer approved for use in human type 2 diabetes mellitus. Therapeutic options for diabetes in cats are limited.

Objective

To evaluate the effects of pioglitazone in obese cats, which are predisposed to insulin resistance, to assess its potential for future use in feline diabetes mellitus.

Animals

A total of 12 obese purpose-bred research cats (6 neutered males and 6 spayed females, 5-7 years of age, weighing 5.4-9.8 kg).

Methods

Randomized, placebo-controlled 3-way crossover study. Oral placebo or pioglitazone (Actos™; 1 or 3 mg/kg) was administered daily for 7-week periods, with IV glucose tolerance testing before and after each period.

Results

Three mg/kg pioglitazone significantly impro

SUBMITTER: Clark M 

PROVIDER: S-EPMC4895531 | biostudies-literature | 2014 Jan-Feb

REPOSITORIES: biostudies-literature